Metabolic diseases (e.g. obesity, type 2 diabetes, and hypertension) are a rapidly expanding health care concern. Although there is a high demand for novel therapies, the challenges are substantial as existing drugs typically fail due to lack of efficacy or safety, and clinical studies often extremely large and protracted. There is a clear need for a greater understanding of how to treat these diseases to obtain maximal efficacy with minimal side effects and also how to monitor these possibilities effectively.
Disease complexity creates significant challenge in identifying, understanding, treating & for clinical trials. A way to circumvent many of this complexity is with the key integrator for systems biology, Metabolomics.